Comparison · NCT02703272-1ffa16ae
Part 2: Ibrutinib+CIT (RICE or RVICI) vs Part 2: Chemoimmunotherapy: Part 2: Number of Participants Who Proceeded to Stem Cell Transplantation
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Part 2: Ibrutinib+CIT (RICE or RVICI) vs Part 2: Chemoimmunotherapy: Part 2: Number of Participants Who Proceeded to Stem Cell Transplantation. Trial comparisons, record NCT02703272-1ffa16ae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02703272-1ffa16ae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.371 | 0.232 | 0.537 | wilson | |
| Risk in group 2 | 0.438 | 0.231 | 0.668 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0661 | -0.336 | 0.198 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.849 | 0.42 | 1.72 | log | |
| Odds ratio, group 1 over group 2 | 0.76 | 0.228 | 2.53 | log | |
| Number needed to treat, for one fewer participant with the outcome on Part 2: Ibrutinib+CIT (RICE or RVICI) than on Part 2: Chemoimmunotherapy | 15.1 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Part 2: Ibrutinib+CIT (RICE or RVICI) | Participants received ibrutinib based on age group and BSA in combination with CIT (investigator choice of RICE or RVICI) until 3 treatment cycles, transplantation if indicated, or until progressive disease (PD) or unacceptable toxicity. For both regimens, triple intrathecal therapy consisting of methotrexate, corticosteroid, and cytarabine will be administered for central nervous system (CNS) prophylaxis in age-appropriate dosing. Participants of age groups 1-5 years and 6-11 years received ibrutinib 440 mg/m\^2, and age group 12-17 years received Ibrutinib 329 mg/m\^2 (dose selected from Part 1). | 13 | 35 | OG000 |
| Group 2 | Part 2: Chemoimmunotherapy | Participants received CIT (investigator choice of RICE or RVICI) alone based on age group and BSA until 3 treatment cycles, transplantation if indicated, or until PD or unacceptable toxicity. For both regimens, triple intrathecal therapy consisting of methotrexate, corticosteroid, and cytarabine will be administered for CNS prophylaxis in age-appropriate dosing. The RICE regimen was composed of rituximab 750 mg/m\^2, ifosfamide 9 g/m2, carboplatin 635 mg/m\^2, etoposide 300 mg/m\^2, and dexamethasone 100 mg/m\^2. The RVICI regimen was composed of rituximab 750 mg/m\^2, vincristine 1.6 mg/m\^2, idarubicin 20 mg/m\^2, carboplatin 800 mg/m\^2, ifosfamide 10 g/m\^2, and dexamethasone 100 mg/m\^2 (all doses represented as cumulative administered in 1 cycle). | 7 | 16 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Part 2: Number of Participants Who Proceeded to Stem Cell Transplantation
- Description
- Number of participants who proceeded to stem cell transplantation were reported.
- Time frame
- Up to end of the study (Up to 4 year and 4 months)
- Population
- The ITT population consisted of all randomized participants; participants were analyzed based on randomization, regardless of study drug received.
Source ClinicalTrials.gov
Trial
- Title
- A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma
- NCT number
- NCT02703272
- Phases
- PHASE3
- Conditions
- Lymphoma, Non-Hodgkin
- Interventions
- Ibrutinib, Rituximab, Ifosfamide, Carboplatin, Etoposide, Vincristine, Idarubicin, Dexamethasone
- Lead sponsor
- Janssen Research & Development, LLC
- Results first posted
- 2022-12-02
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02703272?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02703272-1ffa16ae